Clinical Trial Update: Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update summarizes results from a Phase 1/2 study evaluating arsenic trioxide in combination with imatinib mesylate for chronic myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED